AIHTA - Publications - Search - Horizon Scanning in Oncology 33rd Prioritisation – 4th quarter 2017

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 33rd Prioritisation – 4th quarter 2017. HSO: 33rd Prioritisation.

[thumbnail of HSO_33rd_Prioritisation.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

For the 33 prioritisation (October 2017), 9 drugs were filtered out of 401 identified and were sent to prioritisation. Of these, 5 drugs were ranked as 'highly relevant' by the expert panel, 4 as 'relevant' and none as 'not relevant'. For 'highly relevant' drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.

Item Type:DSD: Horizon Scanning in Oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Series Name:HSO: 33rd Prioritisation
Deposited on:23 Oct 2017 16:52
Last Modified:15 Jul 2020 17:56

Repository Staff Only: item control page